Streetbeat News

Revenues

LOVFF

Cannara Biotech Inc. reported a 51% YoY revenue increase in Q2 2024, with a wider net loss. The company saw a 68% revenue increase for the first half of fiscal 2024, highlighting its growing influence in the Canadian cannabis market. Despite the revenue growth, the company's net loss widened, but it maintained a positive adjusted EBITDA for the twelfth consecutive quarter. Cannara aims to become a leader in the global cannabis market.

Portfolio Pulse from Jelena Martinovic

May 01, 2024 | 7:45 pm

TAP

Analysts have diverse views on Molson Coors Beverage (NYSE:TAP), with 12 recent evaluations ranging from bullish to bearish. The average 12-month price target is $64.17, down 2.24% from previous estimates. Analyst actions include both downgrades and upgrades, reflecting changing market conditions and company performance. Molson Coors, known for brands like Miller and Coors, shows a positive revenue trend with a 6.13% growth rate but faces challenges in profitability and asset utilization. The company's financial health is marked by a low debt-to-equity ratio, indicating conservative financial management.

Portfolio Pulse from Benzinga Insights

May 01, 2024 | 7:01 pm

MAC

Macerich (NYSE:MAC) received mixed analyst ratings over the past three months, with a recent shift towards a more bearish outlook. The average 12-month price target for MAC is now $15.2, reflecting a 1.94% decrease from the previous target. Analysts from Compass Point, Mizuho, Piper Sandler, Truist Securities, and Citigroup have adjusted their ratings and price targets, indicating varying expectations for the company's performance. Macerich, an S&P 500 company, owns a significant portfolio of mall assets but shows a lower market capitalization and financial performance below industry averages.

Portfolio Pulse from Benzinga Insights

May 01, 2024 | 7:01 pm

ENTG

Entegris (NASDAQ:ENTG) has received mixed analyst ratings over the past three months, with 11 analysts offering evaluations. The ratings range from bullish to indifferent, with no bearish sentiments. The average 12-month price target for ENTG is $146.82, marking a significant increase from the previous target of $121.38. Analysts from firms like Needham, Mizuho, Citigroup, BMO Capital, Keybanc, Craig-Hallum, Goldman Sachs, and UBS have adjusted their ratings and price targets, reflecting various perspectives on the company's performance and market position. Entegris, a supplier of materials and process solutions for high-technology industries, has seen a revenue decline of -14.14% over the last three months but maintains a strong net margin of 4.68%. However, its market capitalization, ROE, ROA, and high debt-to-equity ratio indicate potential financial challenges.

Portfolio Pulse from Benzinga Insights

May 01, 2024 | 7:01 pm

DFIN

Analysts have mixed views on Donnelley Financial Solns (DFIN), with recent ratings showing a bullish trend. The average 12-month price target is set at $72.00, marking a 13.08% increase from the previous target. The company's financial performance shows positive revenue growth but challenges in net margin and ROA, while excelling in ROE and managing debt well.

Portfolio Pulse from Benzinga Insights

May 01, 2024 | 7:00 pm

ZBRA

Analyst opinions on Zebra Technologies (NASDAQ:ZBRA) have shown a positive shift over the past quarter, with recent ratings becoming more bullish. The average 12-month price target for ZBRA has increased to $338.78, up 6.59% from the previous $317.83. Analysts from firms like UBS, Stephens & Co., and Truist Securities have raised their price targets, reflecting optimism about the company's performance despite a significant revenue decline of -32.87% as of December 31, 2023. Zebra Technologies, known for its automatic identification and data capture technology, faces challenges in revenue growth but excels in net margin, ROE, and ROA, indicating efficient cost management and financial health.

Portfolio Pulse from Benzinga Insights

May 01, 2024 | 7:00 pm

CECO

CECO Environmental (NASDAQ:CECO) has received diverse analyst ratings over the past quarter, with a total of 7 analysts offering opinions ranging from bullish to bearish. The recent ratings show an increase in bullish sentiment, with 3 new bullish ratings in the last 30 days. The average 12-month price target for CECO has risen to $27.14, up 15.49% from the previous target of $23.50. Analysts from firms like Craig-Hallum, Needham, HC Wainwright & Co., Northland Capital Markets, and Roth MKM have adjusted their ratings and price targets, reflecting optimism about CECO's market position and financial performance. CECO Environmental, serving various markets including energy, industrial, and others, has shown remarkable revenue growth of 32.05% and strong financial metrics such as net margin, ROE, and ROA, outperforming industry standards.

Portfolio Pulse from Benzinga Insights

May 01, 2024 | 7:00 pm

ACB

CGC

CURLF

GTBIF

TCNNF

TLRY

Following the DEA's announcement to reschedule cannabis, the market cap of major cannabis firms has seen significant changes. Curaleaf, Canopy, Tilray, Aurora, Green Thumb Industries, and Trulieve have experienced fluctuations in market capitalization since their public debuts. The total economic impact of regulated marijuana sales in the U.S. is expected to surpass $112.4 billion in 2024, with sales forecasted to reach $32.1 billion. Market cap growth varies among companies, with some experiencing decreases and others increases.

Portfolio Pulse from Nicolás Jose Rodriguez

May 01, 2024 | 6:25 pm

MMSI

Merit Medical Systems (NASDAQ:MMSI) has been the subject of diverse analyst ratings over the last three months, with 11 analysts offering views that range from bullish to bearish. The recent ratings show a mix of 5 bullish, 5 somewhat bullish, and 1 indifferent, with an upward trend in the 12-month price target to an average of $93.45. Analyst actions include both raises and lowers in ratings and price targets, reflecting ongoing market conditions and company performance. Merit Medical Systems, a medical equipment company, has shown solid financial performance with a revenue growth rate of 10.6%, a net margin of 8.51%, and strong ROE and ROA figures.

Portfolio Pulse from Benzinga Insights

May 01, 2024 | 6:01 pm

PCAR

PACCAR (NASDAQ:PCAR) has been analyzed by 8 analysts in the last three months, showing a mix of bullish to bearish sentiments. Recent ratings indicate a shift towards a more positive outlook, with an average 12-month price target of $125.38, marking an 8.24% increase from the previous target. Analyst actions include both upgrades and downgrades, reflecting responses to market conditions and PACCAR's performance. The company, known for its medium- and heavy-duty trucks, has shown strong financial health with a revenue growth of 11.65%, a net margin of 15.61%, and above-average ROE and ROA.

Portfolio Pulse from Benzinga Insights

May 01, 2024 | 6:01 pm